Safety and Efficacy of Fibrin Sealant Grifols (FS Grifols) During Parenchymous Tissue Open Surgeries
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT01754480 |
|
Recruitment Status :
Completed
First Posted : December 21, 2012
Results First Posted : February 8, 2017
Last Update Posted : February 8, 2017
|
Sponsor:
Instituto Grifols, S.A.
Information provided by (Responsible Party):
Grifols Biologicals, LLC ( Instituto Grifols, S.A. )
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Brief Summary:
This study is designed to assess the safety and efficacy of Fibrin Sealant Grifols in patients undergoing open surgical procedures where bleeding may be present on parenchymous tissue (e.g., solid abdominal organs such as the liver). The purpose of this study is to demonstrate that Fibrin Sealant Grifols is not inferior to commercially-available oxidized cellulose pads (Surgicel®) in providing benefit in the time to hemostasis (i.e, the stoppage of bleeding). This study has a Preliminary Part (I) for study teams to become familiar with the application of Fibrin Sealant Grifols and to assess safety and a Primary Part (II) to assess the safety and efficacy of Fibrin Sealant Grifols. In both parts of the study, patients will be randomized in a 1:1 ratio to either Fibrin Sealant Grifols or Surgicel.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Parenchymous Tissue Surgical Bleeding | Biological: Fibrin Sealant Grifols Device: Surgicel® | Phase 3 |
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 325 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Primary Purpose: | Treatment |
| Official Title: | A Prospective, Single-blind, Randomized, Phase III Study to Evaluate the Safety and Efficacy of Fibrin Sealant Grifols (FS Grifols) as an Adjunct to Hemostasis During Parenchymous Tissue Open Surgeries |
| Study Start Date : | March 2013 |
| Actual Primary Completion Date : | December 2015 |
| Actual Study Completion Date : | December 2015 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Fibrin Sealant Grifols
Fibrin Sealant Grifols consisting of 3 mL fibrinogen and 3 mL thrombin in separate syringes assembled on a syringe holder (6 mL of solution in total).
|
Biological: Fibrin Sealant Grifols
Combination of 3 mL fibrinogen and 3 mL thrombin, in separate syringes assembled on a syringe holder (6 mL of solution in total), applied topically to the target bleeding site. |
|
Active Comparator: Surgicel®
Surgicel® is a sterile, absorbable knitted fabric prepared by the controlled oxidation of regenerated cellulose.
|
Device: Surgicel®
Up to four Surgicel® sheets applied to the target bleeding site according to Package Insert instructions and the surgeon's usual clinical practice.
Other Names:
|
Primary Outcome Measures :
- Proportion of Subjects Achieving Hemostasis by Four Minutes After Treatment Start [ Time Frame: From start of treatment until 4 minutes after treatment start ]Subjects achieving hemostasis at the target bleeding site by 4 minutes following the start of treatment without the occurrence of re-bleeding until the completion of surgical closure.
Secondary Outcome Measures :
- Proportion of Subjects Achieving Hemostasis by Three Minutes After Treatment Start [ Time Frame: From start of treatment until 3 minutes after treatment start ]Subjects achieving hemostasis at the target bleeding site by 3 minutes following the start of treatment without the occurrence of re-bleeding until the completion of surgical closure.
- Time to Hemostasis [ Time Frame: From start of treatment until 10 minutes after treatment start ]Time in minutes for achievement of hemostasis at the target bleeding site measured from the start of treatment until 10 minutes after treatment start.
- Cumulative Proportion of Subjects Having Achieved Hemostasis at the Target Bleeding Site by Specified Time Points [ Time Frame: From start of treatment until 10 minutes after treatment start ]
Cumulative proportion of subjects having achieved hemostasis by each of the following time points:
- At 2 minutes following start of study treatment
- At 5 minutes following start of study treatment
- At 7 minutes following start of study treatment
- At 10 minutes following start of study treatment
- Prevalence of Treatment Failures [ Time Frame: From start of treatment until 10 minutes after treatment start ]Protocol-defined bleeding at the target bleeding site after the start of treatment or the use of alternative hemostatic treatments (with exception of reversal of heparin) or maneuvers at the target bleeding site after the start of treatment.
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | Child, Adult, Older Adult |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Hemoglobin (Hgb) ≥ 8.0 g/dL at Baseline (within 24 hours prior to surgical procedure).
- Require elective (non-emergency), open (non-laparoscopic), hepatic resection (anatomic or non-anatomic resections of at least one anatomical hepatic segment, or equivalent tissue volume).
- A target bleeding site can be identified.
- Target bleeding site is identified on the cut raw liver surface (resection area).
- Target bleeding site has moderate bleeding according to the Investigator's judgment.
Exclusion Criteria:
- Require hepatic resection due to trauma.
- Infection in the anatomic surgical area.
- History of severe (e.g. anaphylactic) reactions to blood or to any blood-derived product.
- Previous known sensitivity to any Fibrin Sealant Grifols component or any Surgicel® component.
- Females who are pregnant or nursing a child at Baseline (within 24 hours prior to surgical procedure).
- Receiving an organ transplant during the same surgical procedure.
- Undergone a therapeutic surgical procedure within 30 days from the screening visit.
- A target bleeding site cannot be identified.
- The target bleeding site has a mild or severe bleeding.
- Occurrence of major intraoperative complications that require resuscitation or deviation from the planned surgical procedure.
- Application of any topical haemostatic material on the resection surface of the liver prior to application of study treatment.
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01754480
Locations
Show 33 study locations
Sponsors and Collaborators
Instituto Grifols, S.A.
| Responsible Party: | Instituto Grifols, S.A. |
| ClinicalTrials.gov Identifier: | NCT01754480 |
| Other Study ID Numbers: |
IG1102 |
| First Posted: | December 21, 2012 Key Record Dates |
| Results First Posted: | February 8, 2017 |
| Last Update Posted: | February 8, 2017 |
| Last Verified: | December 2016 |
Keywords provided by Grifols Biologicals, LLC ( Instituto Grifols, S.A. ):
|
Fibrin Sealant Parenchymous tissue open surgery Hepatic Resection Oxidized cellulose pads |
Additional relevant MeSH terms:
|
Fibrin Tissue Adhesive Hemostatics Coagulants |